Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q4 EPS of ($0.75), $0.07 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $13.28 million versus the consensus estimate of $14.91 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Sell Recreational Cannabis as "Medicine"- Federal Class Action Alleges a "Concerted Campaign"
• Sprinklr Inc (CXM) PT Raised to $7.50 at Cantor Fitzgerald